Full text is available at the source.
Abstract
The effectiveness of combining sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for type 2 diabetes mellitus remains uncertain.
- Comparing combined therapy to monotherapy could provide insights into cardiovascular and kidney outcomes.
- The analysis aims to clarify whether using both SGLT2i and GLP-1RA is more beneficial than using either treatment alone.
- Current evidence does not definitively establish the superiority of combined therapy over monotherapy.
Simplified